Attovia Therapeutics (NASDAQ:ATTO) Major Shareholder Purchases 382,352 Shares of Stock

Posted by Teresa Graham on Aug 10th, 2026

Attovia Therapeutics, Inc. (NASDAQ:ATTO – Get Free Report) major shareholder Global Strategic Fund Venbio bought 382,352 shares of the business’s stock in a transaction dated Thursday, August 6th. The shares were bought at an average cost of $17.00 per share, for a total transaction of $6,499,984.00. Following the completion of the transaction, the insider directly owned 4,181,367 shares of the company’s stock, valued at $71,083,239. This trade represents a 10.06% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Attovia Therapeutics Trading Down 1.6%

Shares of NASDAQ:ATTO traded down $0.33 during midday trading on Monday, reaching $19.84. The company had a trading volume of 376,495 shares, compared to its average volume of 342,531. Attovia Therapeutics, Inc. has a 1-year low of $18.50 and a 1-year high of $22.79.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in Attovia Therapeutics stock. BlackRock Inc. lifted its position in Attovia Therapeutics, Inc. (NASDAQ:ATTO – Free Report) by 23.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 164,358 shares of the company’s stock after acquiring an additional 31,189 shares during the period. BlackRock Inc.’s holdings in Attovia Therapeutics were worth $317,000 as of its most recent SEC filing.

Attovia Therapeutics Company Profile

(Get Free Report)

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.